These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 13269837)

  • 41. [Antibody response after administration of influenza monovaccine and bivaccine (type A2 and B)].
    HRBKA A; MALEK J
    Cesk Epidemiol Mikrobiol Imunol; 1962 Mar; 11():79-82. PubMed ID: 14449475
    [No Abstract]   [Full Text] [Related]  

  • 42. Adjuvant influenza adenovirus vaccine.
    MEIKLEJOHN G
    JAMA; 1962 Feb; 179():594-7. PubMed ID: 14472203
    [No Abstract]   [Full Text] [Related]  

  • 43. A TRIAL OF OIL-ADJUVANT INFLUENZA VACCINE IN A NON-EPIDEMIC SEASON.
    HOWELL RW; STOTT AN
    Br J Ind Med; 1964 Oct; 21(4):259-64. PubMed ID: 14249893
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunologic evaluation of 10 different adjuvants for use in vaccines for chickens against highly pathogenic avian influenza virus.
    Lone NA; Spackman E; Kapczynski D
    Vaccine; 2017 Jun; 35(26):3401-3408. PubMed ID: 28511853
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of thymosin alpha-1 (Zadaxin) as a co-adjuvant in influenza vaccines: a review.
    Panatto D; Amicizia D; Lai PL; Camerini R; De Rosa A; Gasparini R
    J Prev Med Hyg; 2011 Sep; 52(3):111-5. PubMed ID: 22010537
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Proteosome-adjuvanted intranasal influenza vaccines: advantages, progress and future considerations.
    Burt D; Mallett C; Plante M; Zimmermann J; Torossian K; Fries L
    Expert Rev Vaccines; 2011 Mar; 10(3):365-75. PubMed ID: 21434804
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial.
    Roman F; Vaman T; Gerlach B; Markendorf A; Gillard P; Devaster JM
    Vaccine; 2010 Feb; 28(7):1740-5. PubMed ID: 20034605
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Different influenza vaccine formulations and adjuvants for childhood influenza vaccination.
    Esposito S; Principi N
    Vaccine; 2011 Oct; 29(43):7535-41. PubMed ID: 21820478
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison between a conventional subunit vaccine and the MF59-adjuvanted subunit influenza vaccine in the elderly: an evaluation of the safety, tolerability and immunogenicity.
    Sindoni D; La Fauci V; Squeri R; Cannavò G; Bacilieri S; Panatto D; Gasparini R; Amicizia D
    J Prev Med Hyg; 2009 Jun; 50(2):121-6. PubMed ID: 20099444
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Relative antigenic potency in man of polyvalent influenza virus vaccines containing isolated hemagglutinins or intact viruses.
    Hennessy AV; Davenport FM
    J Immunol; 1966 Aug; 97(2):235-8. PubMed ID: 5921312
    [No Abstract]   [Full Text] [Related]  

  • 51. Avian influenza virus vaccines containing Toll-like receptors 2 and 5 ligand adjuvants promote protective immune responses in chickens.
    St Paul M; Brisbin JT; Barjesteh N; Villaneueva AI; Parvizi P; Read LR; Nagy E; Sharif S
    Viral Immunol; 2014 May; 27(4):160-6. PubMed ID: 24797722
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems.
    Precioso AR; Miraglia JL; Campos LM; Goulart AC; Timenetsky Mdo C; Cardoso MR; Luna E; Mondini G; Guedes Jda S; Raw I
    Vaccine; 2011 Nov; 29(48):8974-81. PubMed ID: 21945258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Prospects for broadly protective influenza vaccines.
    Treanor JJ
    Vaccine; 2015 Nov; 33 Suppl 4():D39-45. PubMed ID: 26338145
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Contribution to the study of the effectiveness of anti-influenza vaccinations with live virus vaccines].
    Cazacu E; Busuioc C; Stoicescu A; Tomi E; Scharf I
    Stud Cercet Inframicrobiol; 1966; 17(5):389-94. PubMed ID: 5964007
    [No Abstract]   [Full Text] [Related]  

  • 55. [Serological response to anti-influenza booster vaccination in a group of aged subjects].
    Crovari-Cuneo P; De Flora S; Vannucci A; Badolati G
    G Ig Med Prev; 1967; 8(5):623-30. PubMed ID: 5605876
    [No Abstract]   [Full Text] [Related]  

  • 56. [Correlation of antineuraminidase antibodies and antihemagglutinins in influenza and following administration of live influenza vaccine].
    Nekliudova LI; Fedorova IuB; Orlova NG
    Vopr Virusol; 1974; (2):173-6. PubMed ID: 4446555
    [No Abstract]   [Full Text] [Related]  

  • 57. Vaccines with the MF59 adjuvant do not stimulate antibody responses against squalene.
    Del Giudice G; Fragapane E; Bugarini R; Hora M; Henriksson T; Palla E; O'hagan D; Donnelly J; Rappuoli R; Podda A
    Clin Vaccine Immunol; 2006 Sep; 13(9):1010-3. PubMed ID: 16960112
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vaccination against influenza.
    FRANCIS T
    Bull World Health Organ; 1953; 8(5-6):725-41. PubMed ID: 13094502
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Development and application of new parenteral adjuvants.
    WOODHOUR AF; JENSEN KE; WARREN J
    J Immunol; 1961 Jun; 86():681-9. PubMed ID: 13786540
    [No Abstract]   [Full Text] [Related]  

  • 60. Immunologic advantages of emulsified influenza virus vaccines.
    DAVENPORT FM; HENNESSY AV; BELL JA
    Mil Med; 1962 Feb; 127():95-100. PubMed ID: 13883722
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.